FDA Approves Breakthrough Drug for Pancreatic Cancer

Patients with advanced pancreatic cancer just got their first major breakthrough in generations.

The FDA approved daraxonrasib this week, a daily pill that nearly doubles how long people with metastatic pancreatic cancer survive. In a study of 500 patients whose cancer had stopped responding to other treatments, those taking the new drug lived a median of 13.2 months compared to just 6.7 months with standard chemotherapy.

What makes this approval historic is what the drug does. It blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases, targeting something scientists spent decades trying to crack.

"This is one of the most anticipated approvals I can think of," said Dr. Andrew Coveler of the Fred Hutch Cancer Center. "This medicine is not a cure but a significant improvement."

The drug targets mutations in the KRAS gene, which controls cell growth. When this gene mutates, it drives pancreatic cancer aggressively. But the protein's structure made it nearly impossible for drugs to attach to it, earning KRAS the label "undruggable" in medical circles.

Revolution Medicines found a solution using what scientists describe as molecular glue. The technology helps the drug bind to multiple KRAS subtypes, opening doors for treating other cancers too.

The approval came more than six months ahead of schedule. "It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible," said FDA acting commissioner Kyle Diamantas.

Former Senator Ben Sasse brought the drug into public view earlier this year when he shared on 60 Minutes how it reduced his pain. The attention was so intense that the FDA allowed expanded access before official approval for patients who qualified.

Pancreatic cancer remains one of the deadliest cancers, partly because it's hard to catch early. About 67,000 Americans will be diagnosed this year, and more than 52,000 will die from it. The five-year survival rate sits at just 13%.

The Ripple Effect

This breakthrough extends beyond pancreatic cancer. Dozens of companies are now developing similar treatments for lung cancer and other KRAS-driven tumors, using the same molecular approach.

"I think this has opened doors for many other companies," said Dr. Pashtoon Kasi of City of Hope Orange County. "Downstream I think there are going to be a lot more trials looking at this approach in other tumor types."

Revolution Medicines is already testing its technology on several other cancers. What was once considered impossible is now becoming a proven path forward.

For families facing pancreatic cancer today, hope just became something measurable in months and years.